Find a Clinical Trial

Showing 191 - 200 of 237 Trials

A Phase I, open-label, multi-center study to evaluate the safety, tolerability, dosimetry andpreliminary activity of [177Lu]Lu-FF58 in patients with selected advanced solid tumors

Principal Investigator:

Ryan H. Moy, MD, PhD

Contact Number:

212-342-5162

NCT Number:

NCT05977322

Population:

Adult

Phase:

I

The purpose of the study is to test the safety and dosing of the study drug, [ 177Lu]Lu-FF58, a radioligand therapy for patients with various types of cancers. The study will also test the ability to identify tumor lesions using the new imaging agent, [68Ga]Ga-FF58, a radioligand imaging agent, and to see if it is safe. Radioligands are a type of cancer medicine in which a radioactive particle is attached to a compound (FF58 in this study). The compound circulates through the bloodstream, binds to proteins found on tumor lesions, and exposes those tumor lesions to radiation. FF58 can be...
A phase 1/1b dose escalation study of abemaciclib and olaparib for recurrent platinum-resistant ovarian cancer

Principal Investigator:

Jason D. Wright, MD

Contact Number:

212-342-5162

NCT Number:

NCT04633239

Population:

Adult

Phase:

I

This study is being done to answer the following question: Can abemaciclib and olaparib be taken safely together in ovarian cancer that has come back? We are asking you to take part in this research study because you have ovarian cancer that has come back. We are trying to determine whether abemaciclib and olaparib can be taken safely and tolerably together in ovarian cancer that has come back. Are you Eligible? (Inclusion Criteria) Must have ovarian cancer that has come back within 6 months of last dose of treatment. Must have received 1-3 prior treatment regimens. Must have lesions seen on...
A PHASE 1, MULTI-CENTER, OPEN-LABEL,DOSE-FINDING STUDY TO EVALUATE THE SAFETY,TOLERABILITY, PHARMACOKINETICS, ANDPHARMACODYNAMICS OF CC-94676 IN SUBJECTSWITH METASTATIC CASTRATION-RESISTANTPROSTATE CANCER

Principal Investigator:

Karie Danielle Keera Runcie, MD

Contact Number:

212-342-5162

NCT Number:

NCT04428788

Population:

Adult

Phase:

I

You are being asked to take part in this study because you have been diagnosed with advanced prostate cancer and the standard drugs to treat your disease (metastatic castration-resistant prostate cancer [mCRPC]) are no longer effective or no effective treatment is known for your type of cancer. This research study will test an investigational drug called CC-94676 (the study drug; also known as BMS-986365). Investigational means the study drug being tested has not been approved by the United States Food and Drug Administration (FDA). CC-94676 is a new experimental drug developed by the sponsor...
A Pilot Study of Neoadjuvant Combination Spartalizumab and Canakinumab Prior to Radical Nephrectomy in Patients with Localized Clear Cell Renal Cell Carcinoma (SPARC-1 Trial)

Principal Investigator:

Karie Danielle Keera Runcie, MD

Contact Number:

212-342-5162

NCT Number:

NCT04028245

Population:

Adult

Phase:

I

The purpose of this study is to study two experimental drugs called canakinumab and spartalizumab produced by Novartis to see if: • It is safe and feasible to give canakinumab and spartalizumab prior to radical nephrectomy? • Canakinumab and spartalizumab can kill cancer cells and bring immune cells into the kidney cancer when hen given to human subjects prior to radical nephrectomy? You are being asked to participate in this study because you have localized kidney cancer and you are planned to have a radical nephrectomy. People who usually have this do not receive any additional...
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors

Principal Investigator:

Karie Danielle Keera Runcie, MD

Contact Number:

212-342-5162

NCT Number:

NCT05176483

Population:

Adult

Phase:

I

The purpose of this study is to evaluate the efficacy of the study drug, XL092 alone and/or in combination of other study drugs such as with nivolumab, nivolumab plus ipilimumab, or nivolumab/relatlimab fixed dose combination as a potential anticancer therapy to treat people with locally advanced or metastatic cancers including advanced renal cell cancer, castration-resistant prostate cancer, bladder cancer, liver cancer, lung cancer, colon cancer, head and neck cancer. Nivolumab has been approved as single agent for the treatment of melanoma, lung cancer, and bladder cancer and in...
A MULTICENTER, OPEN-LABEL PHASE 1/1B DOSE-FINDING, SAFETY, AND PHARMACOKINETIC STUDY OF MBRC-101, AN ANTI-EPHA5 MONOMETHYL AURISTATIN E(MMAE) ANTIBODY DRUG CONJUGATE, IN ADVANCED REFRACTORY SOLID TUMORS

Principal Investigator:

Linda Y. Wu, MD

Contact Number:

212-342-5162

NCT Number:

NCT06014658

Population:

Adult

Phase:

I

The purpose of this research is to determine the dose and dosing regimens of an investigational drug, MBRC-101, that are well tolerated, as well as to evaluate its safety in patients with advanced or metastatic solid tumors that have already received conventional therapy. MBRC-101 is not an approved treatment anywhere in the world. “Investigational” means that the drug has not been approved by any government authority responsible for the regulation of new medicines, such as the U.S. Food and Drug Administration (FDA). This is the first time MBRC-101 is being tested in humans. Are...
A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination with Other Anti-cancer Agents in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

Principal Investigator:

Hua-Jay J Cherng, MD

Contact Number:

212-342-5162

NCT Number:

NCT04970901

Population:

Adult

Phase:

I

This study will look at the safety, effectiveness (efficacy) and tolerability of an investigational drug called loncastuximab tesirine in combination with other anti-cancer drugs polatuzumab vedotin, glofitamab and mosunetuzumab for patients with relapsed or refractory B-cell Non- Hodgkin Lymphoma. Loncastuximab tesirine is an antibody drug conjugate (ADC), which is a type of medicine that combines an antibody (a protein that binds to specific substances in the body) with a chemotherapy drug that can kill cells. The antibody part of the study drug potentially helps direct the chemotherapy to...
A Phase 1a/1b Study of the PI3Ka:RAS Breaker BBO-10203 in Subjects with Advanced SolidTumors (The BREAKER-101 Trial)

Principal Investigator:

Linda Y. Wu, MD

Contact Number:

212-342-5162

NCT Number:

NCT06625775

Population:

Adult

Phase:

I

The purpose of this study is to find the best dose and effects of BBO-10203 when used alone or in combination with Trastuzumab in HER2-positive advanced breast cancer (aBC) or HR- positive, HER2-negative aBC or advanced non-small cell lung cancer (aNSCLC) with a KRAS (Kirsten rat sarcoma) mutation or advanced colorectal cancer (aCRC) with a KRAS mutation.BBO-10203 has not been approved by the Food and Drug Administration (FDA). Trastuzumab is FDA approved but not in combination with BBO-10203. This is a first in human study. Are you Eligible? (Inclusion Criteria) Must be 18 years old or older...
A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT3789 as Monotherapy and in Combination with Docetaxel in Participants with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation

Principal Investigator:

Benjamin Herzberg, MD

Contact Number:

212-342-5162

NCT Number:

NCT05639751

Population:

Adult

Phase:

I

The purpose of this research study is to test the safety of an investigational drug, PRT3789, at different dose levels to find out what effects, good and/or bad, PRT3789 has on Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation. Mutations are changes or alterations in the DNA (genetic material) of your cells. A SMARCA4 mutation has been linked to certain cancers. Investigational means that the study drug is currently being tested and has not been approved for use by any health authority such as the United States (US) Food and Drug Administration (FDA) or any other health or...
A Phase 1 Study of ALN-BCAT as Monotherapy and in Combination with Pembrolizumab inPatients With Advanced or Metastatic Hepatocellular Carcinoma

Principal Investigator:

Linda Y. Wu, MD

Contact Number:

212-342-5162

NCT Number:

NCT06600321

Population:

Adult

Phase:

I

The purpose of this study is to test the safety of an investigational drug called ALN-BCAT, and find out what effects, if any, ALN-BCAT has on people with your type of liver cancer. The effects being studied include: • The frequency and severity of side effects (to determine if the drug is safe) • Whether ALN-BCAT may make tumors smaller • How ALN-BCAT may affect the genes and proteins in your cancer cells • How your body processes ALN-BCAT Are you Eligible? (Inclusion Criteria) Age 18 years or older - Patient able to understand and willing and able to comply with...

Find a Clinical Trial

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Pages